Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 14/20 | 0.55 |
| ▸ | PDGFRA | P16234 | 12/20 | 0.55 |
| ▸ | AXL | P30530 | 2/20 | 0.52 |
| ▸ | MERTK | Q12866 | 1/20 | 0.52 |
| ▸ | MET | P08581 | 3/20 | 0.52 |
| ▸ | LCK | P06239 | 1/20 | 0.52 |
| ▸ | TEK | Q02763 | 1/20 | 0.52 |
| ▸ | KIT | P10721 | 1/20 | 0.51 |
| ▸ | CSF1R | P07333 | 1/20 | 0.51 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.51 |
| ▸ | FLT4 | P35916 | 1/20 | 0.51 |
| ▸ | FLT3 | P36888 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15338413 | 0.93 | KDR (0.52) | KDRPDGFRAAXLMETLCK | |
| SCHEMBL371958 | 0.92 | PDGFRA (0.61) | KDRPDGFRAAXLMERTKMET | |
| SCHEMBL22552999 | 0.88 | KDR (0.52) | KDRPDGFRAKITCSF1RPDGFRB | |
| SCHEMBL371720 | 0.88 | KDR (0.66) | KDRPDGFRAAXLMERTKMET | |
| SCHEMBL371836 | 0.87 | KDR (0.65) | KDRPDGFRAAXLMERTKMET | |
| SCHEMBL371549 | 0.87 | AXL (0.67) | KDRPDGFRAAXLMERTKMET | |
| SCHEMBL371678 | 0.86 | KDR (0.69) | KDRPDGFRAAXLMERTKMET | |
| SCHEMBL372713 | 0.85 | KDR (0.63) | KDRPDGFRAAXLMERTKMET | |
| SCHEMBL371670 | 0.85 | MET (0.60) | KDRPDGFRAAXLMERTKMET | |
| SCHEMBL12024384 | 0.85 | KDR (0.49) | KDRPDGFRAAXLMERTKMET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210253530-A9 | C-MET MODULATORS AND METHODS OF USE | EXELIXIS, INC. | 2021-08-19 | — | — | US | claimed |
| US-20200331860-A1 | C-Met Modulators and Methods of Use | EXELIXIS INC (US) | 2020-10-22 | — | — | US | claimed |
| EP-2101759-B1 | METHODS OF USING MEK INHIBITORS | EXELIXIS INC (US) | 2018-10-10 | — | — | EP | claimed |
| US-20170355678-A1 | C-Met Modulators and Methods of Use | EXELIXIS INC (US) | 2017-12-14 | — | — | US | claimed |
| US-20160185725-A1 | c-Met Modulators and Method of Use | EXELIXIS, INC. | 2016-06-30 | — | — | US | claimed |
| US-20150376133-A1 | C-Met Modulators and Methods of Use | EXELIXIS, INC. | 2015-12-31 | — | — | US | claimed |
| US-20120022065-A1 | C-Met Modulators and Method of Use | EXELIXIS, INC. (US) | 2012-01-26 | — | — | US | claimed |
| WO-2009017838-A2 | COMBINATIONS OF JAK-2 INHIBITORS AND OTHER AGENTS | EXELIXIS, INC. (US) | 2009-02-05 | — | — | WO | claimed |
| US-20080166359-A1 | Methods of using MEK inhibitors | EXELIXIS, INC. | 2008-07-10 | — | — | US | claimed |
| US-20070054928-A1 | c-Met modulators and methods of use | EXELIXIS, INC. (US) | 2007-03-08 | — | — | US | claimed |
| EP-3329918-B1 | C-MET MODULATORS AND METHODS OF USE | EXELIXIS INC (US) | 2022-05-25 | — | — | EP | disclosed |
| US-11124482-B2 | C-met modulators and methods of use | EXELIXIS, INC. (US) | 2021-09-21 | — | — | US | disclosed |
| US-11124482-B2 | C-met modulators and methods of use | EXELIXIS, INC. (US) | 2021-09-21 | — | — | US | disclosed |
| US-20210253530-A9 | C-MET MODULATORS AND METHODS OF USE | EXELIXIS, INC. | 2021-08-19 | — | — | US | disclosed |
| US-20210253530-A9 | C-MET MODULATORS AND METHODS OF USE | EXELIXIS, INC. | 2021-08-19 | — | — | US | disclosed |
| US-20070225307-A1 | C-MET MODULATORS AND METHOD OF USE | EXELIXIS, INC. (US) | 2007-09-27 | — | — | US | disclosed |
| US-20070225307-A1 | C-MET MODULATORS AND METHOD OF USE | EXELIXIS, INC. (US) | 2007-09-27 | — | — | US | disclosed |
| US-20070054928-A1 | c-Met modulators and methods of use | EXELIXIS, INC. (US) | 2007-03-08 | — | — | US | disclosed |
| US-20070054928-A1 | c-Met modulators and methods of use | EXELIXIS, INC. (US) | 2007-03-08 | — | — | US | disclosed |
| US-20070054928-A1 | c-Met modulators and methods of use | EXELIXIS, INC. (US) | 2007-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200331860-A1 | C-Met Modulators and Methods of Use | FLT4, FLT1, MET | KDR 4/4885PDGFRA 63/4885AXL 109/4885 |
| US-20070054928-A1 | c-Met modulators and methods of use | FLT4, FLT1, MET | KDR 4/4885PDGFRA 63/4885AXL 109/4885 |
| US-20120022065-A1 | C-Met Modulators and Method of Use | FLT4, MET, FLT1 | KDR 5/4885PDGFRA 182/4885AXL 241/4885 |
| US-20150376133-A1 | C-Met Modulators and Methods of Use | FLT4, FLT1, MET | KDR 4/4885PDGFRA 63/4885AXL 109/4885 |
| US-20170355678-A1 | C-Met Modulators and Methods of Use | FLT4, FLT1, MET | KDR 4/4885PDGFRA 63/4885AXL 109/4885 |
| US-20210253530-A9 | C-MET MODULATORS AND METHODS OF USE | FLT4, FLT1, MET | KDR 4/4885PDGFRA 63/4885AXL 109/4885 |
| US-20080166359-A1 | Methods of using MEK inhibitors | BRAF, NRAS, KRAS | KDR 1023/4885PDGFRA 1758/4885AXL 769/4885 |
| US-20070225307-A1 | C-MET MODULATORS AND METHOD OF USE | FLT4, MET, FLT1 | KDR 5/4885PDGFRA 182/4885AXL 241/4885 |
| US-20160185725-A1 | c-Met Modulators and Method of Use | FLT4, MET, FLT1 | KDR 5/4885PDGFRA 182/4885AXL 241/4885 |
| US-11124482-B2 | C-met modulators and methods of use | FLT4, FLT1, MET | KDR 4/4885PDGFRA 63/4885AXL 109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.